# Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

> **NCT04546126** · EARLY_PHASE1 · RECRUITING · sponsor: **Benjamin Viglianti** · enrollment: 24 (estimated)

## Conditions studied

- Radiotracer
- Hypertension
- Cholesterol

## Interventions

- **DRUG:** Dexamethasone (Group 2)
- **DRUG:** Cosyntropin (Group 3)
- **COMBINATION_PRODUCT:** PET/CT Scan with FNP-59

## Key facts

- **NCT ID:** NCT04546126
- **Lead sponsor:** Benjamin Viglianti
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04546126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04546126, "Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04546126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*